HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could immunotherapy spare throat cancer patients from losing their voice?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced laryngeal or hypopharyngeal cancer avoid having their voice box removed. The study will enroll 87 adults whose cancer has not been treated before…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M)
Phase: PHASE2 • Sponsor: Matthew Spector • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC